loading
Spero Therapeutics Inc stock is traded at $2.50, with a volume of 230.17K. It is up +1.21% in the last 24 hours and down -13.79% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.47
Open:
$2.49
24h Volume:
230.17K
Relative Volume:
0.06
Market Cap:
$139.78M
Revenue:
$76.19M
Net Income/Loss:
$-1.61M
P/E Ratio:
250.00
EPS:
0.01
Net Cash Flow:
$28.98M
1W Performance:
-11.97%
1M Performance:
-13.79%
6M Performance:
+174.73%
1Y Performance:
+68.92%
1-Day Range:
Value
$2.48
$2.5095
1-Week Range:
Value
$2.45
$2.90
52-Week Range:
Value
$0.5052
$3.22

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name
Name
Spero Therapeutics Inc
Name
Phone
857-242-1600
Name
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Name
Employee
32
Name
Twitter
@spero_tx
Name
Next Earnings Date
2025-03-19
Name
Latest SEC Filings
Name
SPRO's Discussions on Twitter

Compare SPRO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SPRO
Spero Therapeutics Inc
2.50 169.97M 76.19M -1.61M 28.98M 0.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.38 123.00B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
550.50 59.66B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.11 41.84B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
569.12 33.98B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
289.00 27.67B 3.81B -644.79M -669.77M -6.24

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-20-24 Downgrade Evercore ISI Outperform → In-line
Sep-23-22 Upgrade Evercore ISI In-line → Outperform
Oct-01-21 Downgrade Oppenheimer Outperform → Perform
Jan-22-21 Reiterated H.C. Wainwright Buy
Dec-16-20 Initiated Berenberg Buy
Sep-29-20 Initiated Evercore ISI Outperform
Nov-05-19 Reiterated H.C. Wainwright Buy
Sep-09-19 Initiated Janney Buy
Feb-09-18 Initiated Cantor Fitzgerald Overweight
Nov-27-17 Initiated BofA/Merrill Neutral
Nov-27-17 Initiated Oppenheimer Outperform
Nov-27-17 Initiated Stifel Buy
View All

Spero Therapeutics Inc Stock (SPRO) Latest News

pulisher
Jul 16, 2025

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price - simplywall.st

Jul 16, 2025
pulisher
Jul 15, 2025

Why Spero Therapeutics Inc. stock attracts strong analyst attentionTop Momentum Stock Pick - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Spero Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Spero Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser

Jul 15, 2025
pulisher
Jul 01, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average – What’s Next? - Defense World

Jul 01, 2025
pulisher
Jun 28, 2025

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership - Yahoo

Jun 28, 2025
pulisher
Jun 17, 2025

Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025
pulisher
Jun 12, 2025

SPRO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jun 12, 2025
pulisher
Jun 11, 2025

Spero TherapeuticsAdditional Upside Potential Following Positive Phase 3 Results (SPRO) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Takes Position in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Spero Therapeutics Inc (SPRO) Is A Good Stock To Invest In - Stocksregister

Jun 06, 2025
pulisher
Jun 06, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled - MSN

Jun 06, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Sells 25,050 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 04, 2025
pulisher
May 31, 2025

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 31, 2025

Complicated Urinary Tract Infection Oral Antibiotic Approaches Approval - Vax-Before-Travel

May 31, 2025
pulisher
May 30, 2025

Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN

May 30, 2025
pulisher
May 30, 2025

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN

May 30, 2025
pulisher
May 30, 2025

3 Penny Stocks to Watch Now, 5/29/25 - The Globe and Mail

May 30, 2025
pulisher
May 29, 2025

Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter

May 29, 2025
pulisher
May 28, 2025

Biotech Finds Mid-Week Success After Meeting Primary Endpoint - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data - insights.citeline.com

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results - MSN

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics (SPRO) Stock Explodes: Shares Skyrocket Over 200% in Stunning Midday Rally! - Daily Chhattisgarh News

May 28, 2025
pulisher
May 28, 2025

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga

May 28, 2025
pulisher
May 28, 2025

GSK, Spero stop UTI drug trial after early success - Reuters

May 28, 2025
pulisher
May 28, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled By Stocktwits - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics (SPRO) Soars 255% on Phase 3 Success - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results By Investing.com - Investing.com Nigeria

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results - Investing.com Australia

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics’ Phase 3 Trial Meets Primary Endpoint - TipRanks

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee | SPRO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

What's Behind The Big Stock Moves? SPRO, TIL, IMAB.... - Nasdaq

May 28, 2025
pulisher
May 17, 2025

Analyzing Perrigo (NYSE:PRGO) & Spero Therapeutics (NASDAQ:SPRO) - Defense World

May 17, 2025
pulisher
May 15, 2025

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Spero Therapeutics 2025 Q1 Earnings Misses Targets as Net Loss Widens 9.4% - AInvest

May 14, 2025
pulisher
May 14, 2025

Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Spero Therapeutics Advances Phase 3 Trial With Strong Cash Position, Welcomes New CEO - Stock Titan

May 13, 2025

Spero Therapeutics Inc Stock (SPRO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.00
price up icon 3.69%
$35.60
price down icon 2.49%
$104.55
price down icon 0.21%
$28.27
price up icon 16.05%
$112.08
price down icon 0.37%
biotechnology ONC
$279.16
price up icon 3.51%
Cap:     |  Volume (24h):